1MITRA R D, BUTTY V L, SHENDURE J, et al. Digital genotyping and haplotyping with polymerase colonies [ J ]. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100(10) : 5926 -5931.
2The International HapMap Consortium. The international HapMap project [ J ]. Nature, 2003, 426 ( 6968 ) : 789 - 796.
3International HapMap Consortium, FRAZER K A,BALLINGER D G, et al. A second generation human haplotype map of over 3. 1 million SNPs [ J ]. Nature, 2007, 449(7164) :851 -861.
4PESTKA E L, HALE A M, JOHNSON B L, et al. Cytochrome P450 testing for better psychiatric care [ J ]. J Psychosoc Nurs Ment Health Serv, 2007, 45(10) :15 -18.
5BERTILSSON L. Metabolism of antidepressant and neuroleptic drugs by cytochrome p450: clinical and interethnic aspects [J]. Clin Pharmacol Ther, 2007, 82(5) :606 -609.
6DE MORAIS S M, WILKINSON G R, BLAISDELL J, et al. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans[ J ]. J Biol Chem, 1994, 269 (22) : 15419 - 15422.
7DE MORALS S M, WILKINSON G R, BLAISDELL J, et al. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese [J]. Mol Pharmacol, 1994, 46(4) :594 -598.
8NAKAMOTO K, KIDD J R, JENISON R D, et al. Genotyping and haplotyping of CYP2C19 functional alleles on thin-film biosensor chips [ J ]. Pharmacgenet Genomics, 2007, 17(2) :103 - 114.
9FERGUSON R J, DE MORAIS S M, BENHAMOU S, et al. A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of Smephenytoin[J]. J Pharmacol Exp Ther, 1998, 284( 1 ) : 356 - 361.
10IBEANU G C, BLAISDELL J, FERGUSON R J, et al. A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin [ J ]. J Pharmacol Exp Ther, 1999, 290(2) :635 -640.
7Ferguson R.I, De MorNs SM, Benhamou S, et al. A new genetic defect in human CYP2C19:mutation of the initiation codon is responsible for poor metabolism of S2 mephenytoin[ J], J Pharmcol Exp Ther,1998,284( 1 ) :356 -361.
8Shirai N, Furuta T, Moriyama Y, et al. Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazoleon intragastrie pH[ J ].Aliment Pharmaeol Ther ,2001,15 (12) : 1929 - 1937.
9Sakai T, Aoyama N, Kita T, et al. CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects [J]. Pharm Res,2001,18(6) :721 -727.
10Hyttel J, Bogeso KP, Perregaard J, et al. The pharmacological effect of citalopram resides in the (S)-( + )-enantiomer[ J]. J Neural Transm Gen Sect, 1992,88 : 157 - 160.
